title: Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
authors.forename: David B
authors.initials: DB
authors.lastname: Edwards
authors.forename: John
authors.initials: J
authors.lastname: Silverberg
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D001562:Benzimidazoles / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D020521:Stroke / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran